Teva Pharmaceuticals, Teva, WELTRUZA, olanzapine, FDA approval, schizophrenia, long-acting injectable, LAI, subcutaneous injection, SOLARIS trial, Phase 3, SteadyTeq, Medincell

PARSIPPANY, N.J., and TEL AVIV, Israel — October 9, 2026 Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries...

PARSIPPANY, N.J., and TEL AVIV, Israel — October 9, 2026 Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries...